T cell and cytokine signatures as early predictors of response to IL-12/IL-23 inhibition in Crohn’s disease
These findings support the measurement of serum IL-12/IL-23 at week 8 as a simple, early predictor of ustekinumab response in CD, potentially guiding personalised treatment strategies and ultimately long-term response.
Authors
- Fernando Corvillo (ORCID: https://orcid.org/0000-0001-6418-5647)
- Joaquín Poza Cordón (ORCID: https://orcid.org/0000-0002-0501-0107)
- Cristina Seijo Suárez (ORCID: https://orcid.org/0000-0002-3617-7831)
- Eduardo López‐Collazo (ORCID: https://orcid.org/0000-0003-1957-877X)
- María Sánchez Azofra (ORCID: https://orcid.org/0000-0002-7498-2188)
- Laura García Ramírez (ORCID: https://orcid.org/0000-0002-5173-3381)
- Rebeca Perez de Diego
- Alberto López-Lera
- Nestor Díaz-Iglesias
- Eduardo Martín Arranz
- María Dolores Martín-Arranz
- Paula Blanco-San Miguel
- Blanca García-Solís
- José Luis Rueda García
Institutions
- Hospital Universitario La Paz (ES)
- Instituto de Salud Carlos III (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES)
- Hospital La Paz Institute for Health Research (ES)
- Child Health and Development Institute (US)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-03-04
- DOI
- https://doi.org/10.3389/fimmu.2026.1753914
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Instituto de Salud Carlos III